During the past decade, Jewish General Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Jewish General Hospital" are "Hemorrhage" (1 trials), "Secondary Prevention" (1 trials) and "Stroke" (1 trials). Many other conditions were trialed in "Jewish General Hospital" in a lesser frequency.

Most popular intervention types in "Jewish General Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "ASA 100 mg" (1 trials), "dabigatran etexilate" (1 trials), "idarucizumab" (1 trials), "optional ASA as comedication" (1 trials) and "placebo to ASA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jewish General Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Jewish General Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Jewish General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Jewish General Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".